53,000-square-foot facility addresses unique demands of
commercial-scale viral vector production
COSTA
MESA, Calif., June 16,
2022 /PRNewswire/ -- Avid Bioservices, Inc.
(NASDAQ:CDMO), a dedicated contract development and manufacturing
organization (CDMO) focused on development and CGMP manufacturing
services for biotechnology and pharmaceutical companies, today
highlighted the companies' collaborative efforts that enabled the
phase-one opening of its new purpose-built, 53,000-square-foot
viral vector and CGMP facility in Costa
Mesa, California, in only eight months.
The facility was designed and constructed by CRB – a leading
global provider of sustainable engineering, architecture,
construction, and consulting solutions to the life sciences
industry – and built using the company's innovative ONEsolution™
project delivery approach.
By leveraging a single project team to align with Avid on cost
and schedule without sacrificing quality, CRB's design and
execution fulfills Avid's mission to address a critical gap in the
treatment of oncology and rare disease by prioritizing the specific
needs of the unique process development and manufacturing of viral
vectors used in those treatments.
"Expanding our offerings into viral vectors was a natural
adjacency for Avid, as previously explained by our CEO,
Nick Green. However, the work really
came down to finding a design-build partner with the process,
design, and construction expertise to help us deliver a
best-in-class facility within a constrained schedule and budget.
CRB has done a great job filling this need for Avid and partnering
with us to ensure this new facility meets the needs of current and
future clients," said Mike Alston
Jr., director of project engineering for Avid Bioservices.
"We have been able to leverage dedicated design and construction
teams for phase 1 and 2 to enable continuity across the facility,
and also placed a major focus on early procurement and scheduling.
Considering the challenges of the current supply chain environment,
it has been nothing short of remarkable for Avid and CRB to be
opening the doors of Avid's new viral vector process development
labs here in June."
The state-of-the-art facility at full build-out will include
capacity for adherent and suspension cultures. The second phase is
expected to become operational in mid-calendar year 2023.
"When presented with the opportunity to lead and support Avid's
organic growth and expansion of our business in the cell and gene
therapy CDMO space, I was tremendously excited to be a part of the
team. Next when given the project parameters, schedule, budget, the
first thing that came to mind, was ensuring we had trusted partner
that could anticipate our needs and could work collaboratively and
creatively to achieve our goals," said Rami
Barghout, director of viral vector facilities for Avid
Bioservices. "To that end, CRB has been an instrumental partner
technically and in navigating us through construction to achieve
our aims."
"We're so excited to have worked alongside Avid to help them
realize their vision for a facility that answers an important but
unmet need through the commercial-scale production of viral
vectors," said Matthew Khair, CRB's
vice president for the Western Region. "The close collaboration,
enhanced planning and cultural alignment between teams created an
unrivaled project experience and resulted in a facility that can
close that production gap and speed therapies to patients."
About Avid Bioservices,
Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600
company, is a dedicated contract development and manufacturing
organization (CDMO) focused on development and CGMP manufacturing
of biologics. The company provides a comprehensive range of process
development, CGMP clinical and commercial manufacturing services
for the biotechnology and biopharmaceutical industries. With 28
years of experience producing monoclonal antibodies and recombinant
proteins, Avid's services include CGMP clinical and commercial drug
substance manufacturing, bulk packaging, release and stability
testing and regulatory submissions support. For early-stage
programs the company provides a variety of process development
activities, including upstream and downstream development and
optimization, analytical methods development, testing and
characterization. The scope of our services ranges from
standalone process development projects to full development and
manufacturing programs through
commercialization. www.avidbio.com
About CRB:
CRB is a leading provider of sustainable engineering,
architecture, construction, and consulting solutions to the food
and beverage and life sciences industries. Led by its innovative
ONEsolution™ service, CRB provides
successful integrated project delivery for clients
demanding high-quality solutions, on time and within budget.
The company's more than 1,600 employees provide world-class
solutions that drive success and positive change for their clients,
people, and communities. CRB is a privately held company with a
rich history of serving clients throughout the world, consistently
striving for the highest standard of technical knowledge,
creativity, and execution.
CONTACT:
Avid Bioservices Inc.:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Clarity Quest Marketing:
877-887-7611
Bonnie Quintanilla, bonnie@clarityqst.com
CRB:
816-200-5234
Chris Clark, chris.clark@crbgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avid-bioservices-inc-and-crb-highlight-efforts-that-enabled-opening-of-first-phase-of-new-viral-vector-facility-in-california-in-only-eight-months-301569129.html
SOURCE CRB